Astrocytic activation and reactive gliosis may be another promising target for stroke treatment [19] and for the capturing and monitoring of CSVD severity, which was studied using two well-established biomarkers of alterations in the astroglial somata and processes—namely, glial fibrillary acidic protein (GFAP) and Chitinase-3-like protein 1 (CHI3L1). This evidence concerns the gene CHI3L1 and stroke disorder.